
Femasys Announces Todd Creech as Chief Financial Officer

Atlanta, Ga. --- December 14, 2015 --- Femasys Inc., a developer of innovative medical devices for the women's healthcare market today announced the appointment of Todd A. Creech as Chief Financial Officer. Mr. Creech will serve as Femasys' principal financial and accounting officer, will report to Kathy Lee-Sepsick, President and CEO, and will be responsible for all financing, accounting, corporate development and investor activities.

"Todd has a tremendous amount of financial and corporate development experience in the Life Sciences industry. We are honored to welcome Todd to the Femasys team as we enter the next critical phase of growth while pursuing our vision of expanding healthcare options for women with our innovative medical devices," said Kathy Lee-Sepsick, Femasys' President and CEO. "Todd's proven track record and financial leadership is exemplified by his success with numerous debt and equity financings to support the development of late-stage programs, regulatory approvals as well as commercial activities."

Mr. Creech previously served as the Chief Financial Officer of ZS Pharma, Inc., from August 2013 until June 2015 and was part of the team responsible for taking the company public, completing a successful secondary offering, disseminating key clinical data, and positioning the company for M&A discussions and eventual acquisition. During his tenure at ZS Pharma, Mr. Creech helped raise approximately \$360 million in debt and equity financing.

Prior to ZS Pharma, Mr. Creech was CFO and Vice President of Business Development at SARcode Bioscience, where he led all financing, legal, accounting, and corporate development activities. Shire Pharmaceuticals acquired SARcode in April 2013. Prior to SARcode, Mr. Creech was CFO of Sirion Therapeutics, an ophthalmic pharmaceutical company. During his tenure, he raised \$100 million in debt and equity financing to support the development of six late-stage clinical programs and two NDA approvals, and he also helped lead the sale of Sirion's drug assets to Alcon and Bausch & Lomb.

Mr. Creech worked with NovaQuest, the investment group within Quintiles, Inc., where he structured, placed, and managed capital investments into US-emerging biotech and specialty pharmaceutical companies. Prior to his work with NovaQuest, he cofounded Centice, an optical sensor spin out from Duke University, in 2003. Mr. Creech has an additional 10 years of experience consulting to biotech and high-tech companies while at SRI International and Andersen Consulting. Mr. Creech holds bachelor's degrees in finance and accounting from Miami University of Ohio and an MBA from Duke University.

"This is an extremely exciting time to be joining Femasys especially as the company prepares to commence its pivotal trial of FemBloc™ which is designed to provide women with the first non-surgical permanent contraception option delivered in exclusively in the office.," said Mr. Creech. "I look forward to working closely with the Femasys team to achieve its financial and strategic goals."

ABOUT FEMASYS INC.

Femasys Inc., based in Atlanta, GA, is a privately held corporation committed to transforming women's healthcare worldwide by expanding options for women with innovative medical devices and next generation advancements providing significant clinical impact. Additional information about Femasys and the Company's products can be found at www.femasys.com Femasys has developed a groundbreaking non-surgical female sterilization device (FemBloc™ Permanent Contraceptive System) that allows physicians to deliver exclusively in their office a Biopolymer through a catheter-based Delivery System to permanently block the fallopian tubes in a procedure that substantially reduces patient risks and costs by eliminating the use of anesthesia and permanent implants. The company has also expanded options for women with its two commercially available products for diagnosis of infertility (FemVue® Saline-Air device) and cervical cancer (FemCerv® Endocervical Sampler) that present significant advantages for the patient, physician, and healthcare system.

Femasys, FemBloc, FemVue and FemCerv are registered trademarks of Femasys Inc. All rights reserved.

Source: Femasys Inc.